Singapore Clinical Trial: A randomised, double-blind, placebo-controlled trial with an open-label extension to assess the pharmacokinetics, safety, and efficacy of empagliflozin tablets in paediatric patients with chronic kidney disease (EMPA-KIDNEY® Kids)

Singapore, March 28 -- The Health Sciences Authority received information related to the study titled 'A randomised, double-blind, placebo-controlled trial with an open-label extension to assess the pharmacokinetics, safety, and efficacy of empagliflozin tablets in paediatric patients with chronic kidney disease (EMPA-KIDNEY® Kids)'. The following are the other relevant details related to the trial:

Therapeutic Area: Paediatrics

Trial Centre(s): KK Women's & Children's Hospital National University Hospital

Trial Status: Ongoing, Recruiting

Principal Investigator(s): Dr Esther Leow Sharon Teo

Published by HT Digital Content Services with permission from Health Daily Digest....